Details for Patent: 8,673,902
✉ Email this page to a colleague
Title: | Method of treating otic infections with moxifloxacin compositions |
Abstract: | Ophthalmic, otic and nasal compositions containing a new class of antibiotics (e.g., moxifloxacin) are disclosed. The compositions preferably also contain one or more anti-inflammatory agents. The compositions may be utilized to treat ophthalmic, otic and nasal conditions by topically applying the compositions to the affected tissues. |
Inventor(s): | Cagle; Gerald (Fort Worth, TX), Abshire; Robert L. (Fort Worth, TX), Stroman; David W. (Irving, TX), Yanni; John M. (Burleson, TX) |
Assignee: | Alcon Pharmaceuticals, Ltd. (Fribourg, CH) |
Filing Date: | Nov 03, 2009 |
Application Number: | 12/611,510 |
Claims: | 1. A method of treating otic infections commonly associated with at least one of P. aeruginosa and H. influenzae, which comprises topically applying to the affected otic tissue a therapeutically effective amount of a topical otic pharmaceutical composition comprising moxifloxacin or a pharmaceutically useful hydrate or salt thereof at a concentration of 0.1 to 1.0 wt. % and a pharmaceutically acceptable vehicle therefor. 2. A method of treating otic infections commonly associated with at least one of P. aeruginosa and H. influenzae and attendant inflammation, which comprises topically applying to the affected otic tissue a therapeutically effective amount of a topical otic pharmaceutical composition comprising moxifloxacin or a pharmaceutically useful hydrate or salt thereof at a concentration of 0.1 to 1.0 wt. %, an anti-inflammatory effective amount of a steroidal or non-steroidal anti-inflammatory agent, and a pharmaceutically acceptable vehicle therefor. 3. A method according to claim 2, wherein the anti-inflammatory agent comprises a glucocorticoid. 4. A method according to claim 3, wherein the glucocorticoid is selected from the group consisting of dexamethasone, rimexolone, prednisolone, fluorometholone, hydrocortisone, mometasone, fluticasone, beclomethasone, flunisolide, triamcinolone and budesonide. 5. A method according to claim 2, wherein the anti-inflammatory agent comprises a non-steroidal agent selected from the group consisting of prostaglandin H synthetase inhibitors, PAF antagonists, and PDE IV inhibitors. 6. A method according to claim 2, wherein the anti-inflammatory agent comprises dexamethasone. 7. A method according to claim 2, wherein the anti-inflammatory agent comprises nepafenac. 8. A topical composition method according to any one of claims 1, 2, 6 or 7, wherein the composition contains moxifloxacin or a pharmaceutically useful hydrate or salt thereof at a concentration of about 0.35 wt. %. 9. A method according to any one of claims 1, 2, 6, and 7, wherein the composition contains moxifloxacin or a pharmaceutically useful hydrate or salt thereof at a concentration of 0.35 to 1 wt. %. |